S&P Global Ratings assigned and affirmed the "A" rating on Seattle-based Fred Hutchinson Cancer Research Center's following bonds:
- Series 2017A revenue bonds
- Series 2017B revenue bonds
- Series 2017C revenue bonds
- Series 2015A revenue bonds
- Series 2011A revenue bonds
- Series 2009A revenue bonds
The outlook is positive, reflecting the cancer center's strengthening balance sheet in fiscal year 2016 and the subsequent liquidation of a portion of its stock in Seattle-based Juno Therapeutics, which bolstered the cancer center's cash and investments during the past two fiscal years.